ES2564092T3 - Exotoxinas de pseudomonas mutadas con antigenicidad reducida - Google Patents

Exotoxinas de pseudomonas mutadas con antigenicidad reducida Download PDF

Info

Publication number
ES2564092T3
ES2564092T3 ES10179539.1T ES10179539T ES2564092T3 ES 2564092 T3 ES2564092 T3 ES 2564092T3 ES 10179539 T ES10179539 T ES 10179539T ES 2564092 T3 ES2564092 T3 ES 2564092T3
Authority
ES
Spain
Prior art keywords
essay
exotoxins
reduced antigenicity
amino acid
mutated pseudomonas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10179539.1T
Other languages
English (en)
Inventor
Ira H. Pastan
Masanori Onda
Satoshi Nagata
David Fitzgerald
Robert Kreitman
Byungkook Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of ES2564092T3 publication Critical patent/ES2564092T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Exotoxina A de Pseudomonas ("PE") aislada, en la que dicha PE tiene una sustitución de alanina, glicina, serina o glutamina en lugar del resto aminoacídico E548, en la que el resto aminoacídico E548 se define en referencia a la secuencia de aminoácidos de la PE nativa (SEQ ID NO:1).

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
los promotores T7, trp, lac o λ, un sitio de unión a ribosomas y preferentemente una señal de terminación de la transcripción. Para células eucariotas, las secuencias de control pueden incluir un promotor y preferentemente un potenciador derivado de genes de inmunoglobulinas, SV40, citomegalovirus y una señal de poliadenilación y pueden incluir secuencias donadoras y aceptoras de corte y empalme. Las casetes de la invención pueden transferirse a la
5 célula hospedadora elegida por procedimientos bien conocidos como la transformación por cloruro de calcio o la electroporación para E. coli y el tratamiento con fosfato de calcio, la electroporación o la lipofección para células de mamíferos. Las células transformadas con las casetes pueden seleccionarse por la resistencia a antibióticos conferida por genes contenidos en las casetes, como los genes amp, gpt, neo e hyg.
10 [00127] El experto reconocerá que es posible hacer modificaciones en un ácido nucleico que codifica un polipéptido de la presente invención (es decir, PE o un inmunoconjugado formado a partir de una PE de la invención) sin disminuir su actividad biológica. Algunas modificaciones pueden hacerse para facilitar la clonación, la expresión, o la incorporación de la molécula de reconocimiento en una proteína de fusión. Tales modificaciones son bien conocidas para los expertos en la técnica e incluyen, por ejemplo, codones de terminación, una metionina añadida al extremo
15 amino para proporcionar un sitio de iniciación, aminoácidos adicionales colocados en cualquiera de los extremos para crear sitios de restricción localizados convenientemente o aminoácidos adicionales (como poli-His) para facilitar las etapas de purificación.
[00128] Además de mediante procedimientos recombinantes, los inmunoconjugados y las PE de la presente
20 invención pueden construirse también en parte o en su totalidad mediante síntesis peptídica estándar. La síntesis en fase sólida de los polipéptidos de la presente invención de menos de 50 aminoácidos de longitud puede realizarse mediante la unión del aminoácido C-terminal de la secuencia a un soporte insoluble, seguida de la adición secuencial de los aminoácidos restantes de la secuencia. Las técnicas para la síntesis en fase sólida se describen en Barany y Merrifield, THE PEPTIDES: ANALYSIS, SYNTHESIS, BIOLOGY. Vol. 2: SPECIAL METHODS IN
25 PEPTIDE SYNTHESIS, parte A, págs. 3-284; Merrifield y col., J. Am. Chem. Soc. 85: 2149-2156 (1963) y Stewart y col., SOLID PHASE PEPTIDE SYNTHESIS, 2a edición, Pierce Chem. Co., Rockford, IL, EE. UU. (1984). Es posible sintetizar proteínas de mayor longitud por condensación de los extremos amino y carboxilo de fragmentos más cortos. Los procedimientos para formar enlaces peptídicos por activación de un extremo carboxilo terminal (p. ej., mediante el agente de acoplamiento N, N’-diciclohexilcarbodiimida) son conocidos para los expertos.
30
B. Purificación
[00129] Una vez expresados, los inmunoconjugados y PE recombinantes de la presente invención pueden purificarse según procedimientos estándar de la técnica, como precipitación con sulfato de amonio, columnas de
35 afinidad, cromatografía en columna y similares (véase generalmente R. Scopes, PROTEIN PURIFICATION, Springer-Verlag, NY, EE. UU. (1982). Se prefieren composiciones sustancialmente puras con una homogeneidad de al menos aproximadamente el 90-95% y una homogeneidad del 98 al 99% es la más preferida para usos farmacéuticos. Una vez purificados, parcialmente o hasta homogeneidad, según se desee, si han de usarse terapéuticamente, los polipéptidos no deberán contener sustancialmente ninguna endotoxina.
40 [00130] Los procedimientos para la expresión de anticuerpos de una sola cadena y/o su plegamiento para obtener una forma activa apropiada, incluidos los anticuerpos de una sola cadena de bacterias como E. coli , han sido descritos y son bien conocidos y aplicables a los anticuerpos de esta invención. Véase Buchner y col., Anal. Biochem. 205: 263-270 (1992); Pluckthun, Biotechniology 9: 545 (1991); Huse y col., Science 246: 1275 (1989) y
45 Ward y col., Nature 341: 544 (1989), todos ellos incorporados por referencia en este documento.
[00131] Frecuentemente, las proteínas heterólogas funcionales de E. coli o de otras bacterias se aíslan de cuerpos de inclusión y requieren la solubilización mediante desnaturalizantes fuertes y un subsiguiente plegamiento. Durante la etapa de solubilización, tal como es bien conocido en la técnica, debe haber presente un agente reductor para
50 separar los puentes disulfuro. Un tampón de ejemplo con un agente reductor es: Tris 0,1 M pH 8, guanidina 6 M, EDTA 2 mM, DTE (ditioeritritol) 0,3 M. La reoxidación de los puentes disulfuro puede tener lugar en presencia de reactivos tiólicos de bajo peso molecular en forma reducida y oxidada, tal como se describe en la publicación de Saxena y col., Biochemistry 9: 5015-5021 (1970), incorporada por referencia en este documento, y especialmente tal como describen Buchner y col., cita anterior.
55 [00132] Típicamente la renaturalización se consigue por dilución (p. ej., 100 veces) de la proteína desnaturalizada y reducida en el tampón de plegamiento. Un tampón de ejemplo es Tris 0,1 M pH 8,0, L-arginina 0,5 M, glutatión oxidado 8 mM y EDTA 2 mM.
20
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
Fusión Inmunización Refuerzo Ratón Título Procedimiento Número de final de cribado clones finales (c) 14 M1-ip x 4 D553E-ip C3H Hej 3 x 104 ICC con 0 CD30 15 M1-ipx3+ III-ip A/J 3x105 ICCcon30 3 D553E x 2 16 M1-ip x 3 + D553E-ip A/J 3 x 105 ICC con 13 D553E x 2 CD30
(c) Los clones se seleccionan por su alta afinidad relativa en ICC-ELISA con M40-3 como estándar. M1: M1(dsFv)-PE38, D553E: mutante de LMB-2 con D553E, R276G: mutante de M1(scFv)PE38 con R276G, III: dominio III
Tabla 2. Lista de MAb estudiados
Nombre
Epítopo Isotipo Título (log µl/µg) Afinidad (nM)
IP43
1a γ/I 2,6 0,10
IP62
1a γ/I 2,5 0,2
IP57
1a γ/I 1,9 0,00039
IP11
1b γ/I 2,6 6*
IP39
1b γ/I 2,8 0,93*
IP47
1b γ/I 2,8 0,47*
IP70
1b γ/I 2,5 58*
IP48
1b γ/I 2,7 3,3*
IP1
1b γ/I 2,6 5,80
IP35
1b γ/I 2,8 3,70
IP36
1b γ/I 2,6 3,60
IP42
1b γ/I 2,5 43
IP34
2a γ/I 2,7 0,11*
IP29
2b γ/I 2,8 20
IP63
2b γ/I 2,7 5
IP2
2b γ/I 2,7 0,30
IP15
2c γ/I 2,6 5,3
IP22
2c γ/I 2,6 3,4*
IP51
2c γ/I 2,2 3,10
IP76
2c γ/I 3,0 0,19
IP83
2c γ/I 2,5 0,43
IP9
3a γ/I 2,4 4,80
IP18
3a γ/I 2,5 0,09*
IP16
3a γ/I 2,5 0,24*
IP32
3a γ/I 2,7 33
IP44
3b γ/I 2,5 0,14
IP45
3b γ/I 2,9 0,47
IP58
3b γ/I 2,4 0,24
IP7
4a γ/I 2,7 0,04
IP10
4a γ/I 2,1 0,04
IP31
4a γ/I 2,9 0,27*
IP37
4a γ/I 2,7 1,40
IP49
4a γ/I 1,7 2,60
IP3
4a γ/I 2,6 0,00038
IP27
4a γ/I 2,7 16*
IP72
4a γ/I 2,8 4,4*
IP14
4b γ/I 2,6 81
IP82
4b γ/I 2,7 11*
IP86
4b γ/I 2,9 0,41*
IP13
5 γ/I 2,6 1,2
IP20
5 γ/I 2,3 0,1
29
imagen27
Tabla 4. CI50 de las inmunotoxinas preparadas por mutación de la PE en restos que afectan a la unión a diferentes epítopos
Ensay o n° 14
0,7
Ensay o n° 13
0,44
Ensay o n° 12
1,8
Ensay o n° 11
1,0
Ensay o n° 10
0,9 0,7 0,7
Ensay o n° 9
0,7 0,55 30 >100 0,4
Ensay o n° 8
2,0 1,9(?) 4,4 5,0/6,2
Ensay o n° 7
0,2 0,45
Ensay o n° 6
4 6 5 10
Ensay o n° 5
3,3 3,7 4,2 6,5
Ensay o n° 4
3,4 4,5
Ensay o n° 3
1,0 1,0
Ensay o n° 2
1,0 2,0 1,1 3,0
Ensay o n° 1
1,2ng/ml 3,0 0,72 0,72 1,5 2,1
N° de MAb bloqueados al mutar este resto
8 8 8 3 3 3 3 3/3 8 3 3 3
N° de MAb en este grupo epitópico
37 8 3 3 3 3/3 8 3 3 3
Epítopo
1 1 1 2c 5 2c 1/5/7 7 5/7 5/1 5/2/7 1 5 2 7
IT con los res tos designados mutados en la secuencia de la PE
InmunotoxinaHA22(control) N314A* N314S Q332A R467A R490A R538A* Q332A R490AK590A/K606A/613del* K590A R490AK590A* Q332AR490A* K606A* R490A R538AK590A* Q332S R490S* R538S* K590S
31 32
(continuación) */ La mutación redujo la citotoxicidad en más del 50%
Ensay o n° 14
0,9 0,8
Ensay o n° 13
0,7
Ensay o n° 12
1,0 0,8
Ensay o n° 11
0,75 0,6
Ensay o n° 10
0,8
Ensay o n° 9
Ensay o n° 8
Ensay o n° 7
Ensay o n° 6
Ensay o n° 5
Ensay o n° 4
Ensay o n° 3
Ensay o n° 2
Ensay o n° 1
N° de MAb bloqueados al mutar este resto
17 22 5
N° de MAb en este grupo epitópico
(5) 6
Epítopo
1/2c/5/7 3/1/2c/5/7 3/1/4a/2c/5/7 3/1/4a/2c/5/6/7 3/1/4a/2c/5/6/6/7
IT con los res tos designados mutados en la secuencia de la PE
Q332S R467AR490A K590S R313A Q332SR467A R490AK590S R313A Q332SR432G R467AR490A K590S R313A Q332SR432G R467AR490A R513AK590S R313A Q332SR432G R467AR490A R513AE548S K590S
imagen28
imagen29

Claims (1)

  1. imagen1
ES10179539.1T 2005-07-29 2006-07-25 Exotoxinas de pseudomonas mutadas con antigenicidad reducida Active ES2564092T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70379805P 2005-07-29 2005-07-29
US703798P 2005-07-29

Publications (1)

Publication Number Publication Date
ES2564092T3 true ES2564092T3 (es) 2016-03-17

Family

ID=37709138

Family Applications (6)

Application Number Title Priority Date Filing Date
ES15191395.1T Active ES2660026T3 (es) 2005-07-29 2006-07-25 Exotoxinas de pseudomonas mutadas con antigenicidad reducida
ES10179539.1T Active ES2564092T3 (es) 2005-07-29 2006-07-25 Exotoxinas de pseudomonas mutadas con antigenicidad reducida
ES15191388T Active ES2702650T3 (es) 2005-07-29 2006-07-25 Exotoxinas de pseudomonas mutadas con antigenicidad reducida
ES15191391.0T Active ES2659039T3 (es) 2005-07-29 2006-07-25 Exotoxinas de pseudomonas mutadas con antigenicidad reducida
ES06788523T Active ES2372537T3 (es) 2005-07-29 2006-07-25 Exotoxinas de pseudomonas mutadas con antigenicidad reducida.
ES10179520T Active ES2410783T3 (es) 2005-07-29 2006-07-25 Exotoxinas de pseudomonas mutadas con antigenicidad reducida

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES15191395.1T Active ES2660026T3 (es) 2005-07-29 2006-07-25 Exotoxinas de pseudomonas mutadas con antigenicidad reducida

Family Applications After (4)

Application Number Title Priority Date Filing Date
ES15191388T Active ES2702650T3 (es) 2005-07-29 2006-07-25 Exotoxinas de pseudomonas mutadas con antigenicidad reducida
ES15191391.0T Active ES2659039T3 (es) 2005-07-29 2006-07-25 Exotoxinas de pseudomonas mutadas con antigenicidad reducida
ES06788523T Active ES2372537T3 (es) 2005-07-29 2006-07-25 Exotoxinas de pseudomonas mutadas con antigenicidad reducida.
ES10179520T Active ES2410783T3 (es) 2005-07-29 2006-07-25 Exotoxinas de pseudomonas mutadas con antigenicidad reducida

Country Status (8)

Country Link
US (1) US8907060B2 (es)
EP (6) EP2332970B1 (es)
AT (1) ATE524489T1 (es)
AU (1) AU2006275865B2 (es)
CA (2) CA2941466C (es)
ES (6) ES2660026T3 (es)
PL (3) PL3006456T3 (es)
WO (1) WO2007016150A2 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7989322B2 (en) 2007-02-07 2011-08-02 Micron Technology, Inc. Methods of forming transistors
WO2008109005A2 (en) * 2007-03-02 2008-09-12 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of anti-cd22 immunotoxins and protein-synthesis-inhibiting chemotherapeutic agents in treatment of b cell cancers
ES2525488T3 (es) 2007-09-04 2014-12-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Deleciones en el dominio II de la exotoxina A de pseudomonas que reducen la toxicidad inespecífica
WO2011031441A1 (en) 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
US8936792B2 (en) 2009-09-11 2015-01-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pseudomonas exotoxin a with reduced immunogenicity
WO2011100455A1 (en) 2010-02-12 2011-08-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibition of antibody responses to foreign proteins
DK3434346T3 (da) 2010-07-30 2020-12-07 Medimmune Llc Oprensede aktive polypeptider eller immunokonjugater
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
BR112013006088B1 (pt) 2010-09-15 2022-06-14 Randall J Mrsny Construto de entrega isolado, e, composição farmacêutica
US9206257B2 (en) 2011-04-19 2015-12-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
PE20141454A1 (es) 2011-05-06 2014-10-23 Us Gov Health & Human Serv Inmunotoxina recombinante dirigida a la mesotelina
CN103748107B (zh) 2011-06-09 2020-06-02 美利坚合众国, 由健康及人类服务部部长代表 具有免疫原性较小的t细胞和/或b细胞表位的假单胞菌外毒素a
US8932586B2 (en) 2011-09-06 2015-01-13 Intrexon Corporation Modified forms of Pseudomonas exotoxin A
WO2013039916A1 (en) 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
EP3301110A1 (en) 2011-09-16 2018-04-04 The USA, as represented by The Secretary, Department of Health and Human Services Pseudomonas exotoxin a with less immunogenic b cell epitopes
WO2013059593A1 (en) 2011-10-20 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
PL397167A1 (pl) 2011-11-28 2013-06-10 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
WO2013181543A1 (en) 2012-06-01 2013-12-05 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services High-affinity monoclonal antibodies to glypican-3 and use thereof
CA2882753C (en) 2012-08-21 2021-08-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin domain-specific monoclonal antibodies and use thereof
JP6307085B2 (ja) 2012-09-27 2018-04-04 ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンテッド・バイ・ザ・セクレタリー・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシーズＴｈｅ Ｕｎｉｔｅｄ Ｓｔａｔｅｓ ｏｆ Ａｍｅｒｉｃａ，ａｓ ｒｅｐｒｅｓｅｎｔｅｄ ｂｙ ｔｈｅ Ｓｅｃｒｅｔａｒｙ，Ｄｅｐａｒｔｍｅｎｔ ｏｆ Ｈｅａｌｔｈ ａｎｄ Ｈｕｍａｎ Ｓｅｒｖｉｃｅｓ メソテリン抗体および強力な抗腫瘍活性を惹起するための方法
AU2013343667A1 (en) 2012-11-08 2015-04-02 F. Hoffmann-La Roche Ag HER3 antigen binding proteins binding to the beta-hairpin of HER3
DK2934597T3 (en) 2012-12-20 2019-02-11 Medimmune Llc PROCEDURES FOR PREPARING IMMUNCONJUGATES
JP6584012B2 (ja) * 2013-10-06 2019-10-02 アメリカ合衆国 改変シュードモナス外毒素ａ
EP3054987B1 (en) 2013-10-11 2019-10-09 The United States of America, represented by the Secretary, Department of Health and Human Services Tem8 antibodies and their use
EP3066118B1 (en) 2013-11-06 2020-01-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Alk antibodies, conjugates, and chimeric antigen receptors, and their use
EP3102245B1 (en) 2014-02-05 2021-09-08 Molecular Templates, Inc. Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity
BR112016025866A2 (pt) 2014-05-07 2017-12-12 Applied Molecular Transp Llc composição farmacêutica, método para tratar uma doença anti-inflamatória em um indivíduo, método para tratar uma doença autoimune em um indivíduo, método para tratar um câncer em um indivíduo, uso de uma molécula de fusão que não ocorre naturalmente, método para tratar um distúrbio metabólico em um indivíduo, método para tratar uma doença hepática gordurosa em um indivíduo, método para tratar um distúrbio de deficiência de hormônio de crescimentoem um indivíduo, e, polinucleotídeo que codifica uma molécula de fusão
EP3473271B1 (en) 2014-07-31 2022-07-20 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Human monoclonal antibodies against epha4 and their use
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
EP3350224B1 (en) 2015-09-20 2024-06-19 The United States of America, as Represented By the Secretary, Department of Health and Human Services Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
JP6901493B2 (ja) 2015-11-13 2021-07-14 アメリカ合衆国 抗ｂｃｍａポリペプチド及びタンパク質
WO2017196847A1 (en) 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
WO2017214182A1 (en) 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
CA3031559A1 (en) 2016-08-02 2018-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
US11236171B2 (en) 2016-12-21 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for FLT3 and uses thereof
US11390683B2 (en) 2017-05-18 2022-07-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin polypeptides and proteins
EP3625256A1 (en) 2017-05-19 2020-03-25 The U.S.A. as represented by the Secretary, Department of Health and Human Services Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
WO2019005208A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
CA3066953A1 (en) 2017-06-30 2019-01-03 Lentigen Technology, Inc. Human monoclonal antibodies specific for cd33 and methods of their use
US11795235B2 (en) 2017-09-18 2023-10-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotoxins with albumin binding domain
KR20210076881A (ko) 2018-03-08 2021-06-24 어플라이드 몰레큘라 트랜스포트 인크. 경구 전달용 독소-유래 전달 구조체
WO2020014482A1 (en) 2018-07-12 2020-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Affinity matured cd22-specific monoclonal antibody and uses thereof
US12012463B2 (en) 2018-08-08 2024-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-2 and uses thereof
CN113347997A (zh) 2018-11-07 2021-09-03 应用分子运输公司 用于经口递送异源有效载荷的Cholix衍生的携带体
EP3883608A1 (en) 2019-01-08 2021-09-29 The United States of America, as represented by the Secretary, Department of Health and Human Services Cross-species single domain antibodies targeting mesothelin for treating solid tumors
US12122843B2 (en) 2019-01-22 2024-10-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
MX2022000174A (es) 2019-07-02 2022-05-20 Us Health Anticuerpos monoclonales que se enlazan a egfrviii y sus usos.
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
EP4031250A1 (en) 2019-10-22 2022-07-27 The United States of America, as represented by the Secretary, Department of Health and Human Services High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
WO2021097289A1 (en) 2019-11-15 2021-05-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pegylated recombinant immunotoxins
US20230391852A1 (en) 2020-10-26 2023-12-07 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
MX2023007178A (es) 2020-12-22 2023-06-30 Jiangsu Hengrui Pharmaceuticals Co Ltd Complejo de anticuerpo anti-il-4r o fragmento de enlace a antigeno y uso medico del mismo.
WO2022232612A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
US20240270851A1 (en) 2021-06-09 2024-08-15 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting pd-l1 for treating solid tumors
US20240417446A1 (en) 2021-10-26 2024-12-19 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
CA3240254A1 (en) 2021-12-17 2023-06-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin polypeptides, proteins, and chimeric antigen receptors
WO2024050399A1 (en) 2022-09-01 2024-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
WO2024104584A1 (en) 2022-11-17 2024-05-23 University Of Cape Town Deimmunized pseudomonas exotoxin a
WO2024238346A1 (en) 2023-05-12 2024-11-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies that specifically bind the s2 subunit of sars-cov-2 spike protein and compositions and uses thereof
WO2025014896A1 (en) 2023-07-07 2025-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Humanized 40h3 antibody
AU2024295016A1 (en) 2023-07-20 2026-02-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
WO2025106427A1 (en) 2023-11-14 2025-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)
WO2025171238A1 (en) 2024-02-07 2025-08-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5055303A (en) * 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5621078A (en) * 1989-03-22 1997-04-15 Merck & Co., Inc. Modified pseudomonas exotoxin PE40
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
WO1991018100A1 (en) 1990-05-11 1991-11-28 THE UNITED SATES OF AMERICA, represented by THE SECRETARY, UNITED STATES DEPARTMENT OF COMMERCE Improved pseudomonas exotoxins of low animal toxicity and high cytocidal activity
US5608039A (en) * 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
WO1993017668A1 (en) 1992-03-12 1993-09-16 Alkermes Controlled Therapeutics, Inc. Controlled release acth containing microspheres
CA2136724A1 (en) 1992-06-18 1993-12-23 Ira H. Pastan Recombinant pseudomonas exotoxin with increased activity
US5534496A (en) * 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5747654A (en) * 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5888773A (en) 1994-08-17 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Method of producing single-chain Fv molecules
US6518061B1 (en) 1995-03-15 2003-02-11 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
AU7718696A (en) 1995-10-27 1997-05-15 Merck & Co., Inc. Pseudomonas exotoxin as immunogenic carrier in synthetic conjugate vaccines
US6426075B1 (en) * 1996-11-06 2002-07-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Protease-activatable pseudomonas exotoxin A-like proproteins
US6296843B1 (en) 1998-04-03 2001-10-02 The Penn State Research Foundation Mutagenized IL 13-based chimeric molecules
US20020142000A1 (en) * 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
JP5683766B2 (ja) * 1999-05-27 2015-03-11 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， リプリゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 高い結合親和性を有する免疫結合体
WO2001034645A2 (en) 1999-11-11 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Mutated il-13 molecules and their uses
JP2004502946A (ja) 2000-07-10 2004-01-29 ゼンコー 改変された免疫原性を有するタンパク質ライブラリーを設計するためのタンパク質設計オートメーション
ZA200305980B (en) * 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
US20030113350A1 (en) * 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
DE60236450D1 (de) * 2001-09-26 2010-07-01 Us Health Mutierte anti-cd22-antikörper mit erhöhter affinität zu cd22-exprimierenden leukämiezellen
CA2466443A1 (en) 2001-11-09 2003-05-15 Neopharm, Inc. Selective treatment of il-13 expressing tumors
DE602004027291D1 (de) 2003-11-25 2010-07-01 Us Gov Health & Human Serv Mutierte anti-cd22-antikörper und immunkonjugate
EP2178559B1 (en) * 2007-07-20 2015-06-24 The General Hospital Corporation Recombinant vibrio cholerae exotoxins
ES2525488T3 (es) * 2007-09-04 2014-12-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Deleciones en el dominio II de la exotoxina A de pseudomonas que reducen la toxicidad inespecífica
EP2411416A1 (en) * 2009-03-24 2012-02-01 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Anti-mesothelin antibodies
WO2011031441A1 (en) * 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
US8936792B2 (en) * 2009-09-11 2015-01-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pseudomonas exotoxin a with reduced immunogenicity
US9249225B2 (en) * 2010-05-26 2016-02-02 Regents Of The University Of Minnesota Single chain variable fragment anti-CD133 antibodies and uses thereof
CN103748107B (zh) * 2011-06-09 2020-06-02 美利坚合众国, 由健康及人类服务部部长代表 具有免疫原性较小的t细胞和/或b细胞表位的假单胞菌外毒素a

Also Published As

Publication number Publication date
EP2332970A2 (en) 2011-06-15
CA2616987C (en) 2016-10-11
ATE524489T1 (de) 2011-09-15
ES2702650T3 (es) 2019-03-04
EP3006457A1 (en) 2016-04-13
EP1910407B1 (en) 2011-09-14
EP3006456B1 (en) 2018-09-19
PL3006457T3 (pl) 2018-05-30
ES2660026T3 (es) 2018-03-20
EP1910407A2 (en) 2008-04-16
CA2941466A1 (en) 2007-02-08
AU2006275865B2 (en) 2012-06-28
EP3006456A1 (en) 2016-04-13
CA2616987A1 (en) 2007-02-08
ES2659039T3 (es) 2018-03-13
EP2311854A1 (en) 2011-04-20
AU2006275865A1 (en) 2007-02-08
US8907060B2 (en) 2014-12-09
EP2311854B1 (en) 2013-04-17
US20090142341A1 (en) 2009-06-04
CA2941466C (en) 2019-12-03
EP2332970B1 (en) 2015-12-23
ES2372537T3 (es) 2012-01-23
ES2410783T3 (es) 2013-07-03
WO2007016150A3 (en) 2007-08-09
EP3006458B1 (en) 2017-11-22
EP3006458A1 (en) 2016-04-13
EP3006457B1 (en) 2017-11-22
EP2332970A3 (en) 2011-09-14
PL3006456T3 (pl) 2019-05-31
PL3006458T3 (pl) 2018-05-30
WO2007016150A2 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
ES2564092T3 (es) Exotoxinas de pseudomonas mutadas con antigenicidad reducida
US6147203A (en) Recombinant disulfide-stabilized polypeptide fragments having binding specificity
Chaudhary et al. A rapid method of cloning functional variable-region antibody genes in Escherichia coli as single-chain immunotoxins.
ES2362386T3 (es) Proteínas activas biológicas que tienen estabilidad aumentada in vivo y/o in vitro.
CN105477641B (zh) 生物合成的脯氨酸/丙氨酸无规卷曲多肽及其用途
ES2985999T3 (es) Conjugados de proteínas
US7906624B2 (en) Binding peptidomimetics and uses of the same
KR20030081315A (ko) 화학적으로 합성한 폴리펩티드의 폴딩 방법
ES2870802T3 (es) Métodos de replegado de proteínas a elevado pH
Liu et al. Enabling chemical protein (semi) synthesis via reducible solubilizing tags (RSTs)
US11345745B2 (en) Peptide-hinge-free flexible antibody-like molecule
ES2813501T3 (es) Métodos de replegado de proteínas basados en filtración de flujo tangencial
Kipriyanov et al. Bacterial expression and refolding of single-chain Fv fragments with C-terminal cysteines
Brinkmann et al. Stabilization of a recombinant Fv fragment bybase-loop interconnection and VH-VL permutation
Lu et al. A de novo designed template for generating conformation-specific antibodies that recognize α-helices in proteins
Singh Surface plasmon resonance (SPR) based binding studies of refolded single chain antibody fragments
Martin et al. Engineering novel bioactive mini-proteins on natural scaffolds
Katayama et al. Application of 2, 2′‐dipyridyl disulfide‐mediated thiazolidine ring‐opening reaction to glycoprotein synthesis: Total chemical synthesis of evasin‐3
WO2022080385A1 (ja) ペプチド、およびペプチドを用いる抗体の修飾
KR102140557B1 (ko) 단백질-단백질 결합체를 형성 매개 펩타이드 및 이를 이용한 단백질-단백질 결합체 형성 방법
Whitlow Protein Engineering Strategies
JP2020511519A (ja) 操作された安定なｃｈ２ポリペプチド
Van de Vijver et al. Application of an omonasteine ligation strategy for the total chemical synthesis of the BRD7 bromodomain
Kim et al. Activation of a refolded, berberine-specific, single-chain Fv fragment by addition of free berberine
Hutchinson et al. Characterization of a unique conformational epitope on free immunoglobulin kappa light chains that is recognized by an antibody with therapeutic potential